Targeted Oral Chemotherapy Agents for Metastatic Breast Cancer

<p>Kaitlyn J. Bailey, PharmD (<a href='https://twitter.com/pharmgirl1821'>@pharmgirl1821</a>) describes the mechanisms of action of select CDK46, PI3K, and PARP inhibitors, reviews the outcomes data related to CDK46, PI3K, and PARP inhibitors for treatment of metastatic breast cancer and discusses toxicity management for CDK46, PI3K, and PARP inhibitors. </p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes</a> or the host, Garrett E. Schramm, Pharm.D., <a href='https://twitter.com/garrett_schramm'>@garrett_schramm</a> on Twitter!</p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>